Zimbabwe has rejected a substantial American health deal worth 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential data.
This move came to light after a official document dated December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson later stated that the United States was demanding access to genetic material for research and commercial gain while refused to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further negotiations to secure a agreement acceptable to all parties so the nation's critical HIV programme can proceed.
Wider Implications
This rejection comes after a similar situation in Kenya, where a high court suspended a similar health funding agreement following concerns were filed about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, 16 African countries have to date signed these new health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no corresponding guarantee of access to any medical innovations – like new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our country would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the global health body and its push of one-on-one health agreements were disrupting frameworks previously established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome continued dialogue with our US partners on how future collaboration could be arranged in a manner that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but urged that talks should continue considering much of the nation's Aids initiatives relied on external financing.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group added.
The halted deal emphasises the complex debate between receiving crucial international aid and protecting national sovereignty in an increasingly data-driven world.